Atezolizumab significantly increased OS in the intention-to-treat and PD-L1-expression population (at least 1% PD-L1 on tumor cells or tumor-infiltrating immune cells), 13.8 months for Atezolizumab (95% CI, 11.8 to 15.7) and 9.6 months (95% CI, 8.6 to 11.2) for those who received Docetaxel (HR 0.73, p = 0.0003). Here, CD274 is linked to neoplasm.